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Abstract 
Background: Growing evidence is showing that metastatic cell populations are able to transfer their characteristics 
to less malignant cells. Exosomes (EXOs) are membrane vesicles of endocytic origin able to convey their cargo of 
mRNAs, microRNAs (miRs), proteins and lipids from donors to proximal as well as distant acceptor cells. Our previous 
results indicated that miR-221&222 are key factors for melanoma development and dissemination. The aim of this 
study was to verify whether the tumorigenic properties associated with miR-222 overexpression can be also propa-
gated by miR-222-containing EXOs.
Methods: EXOs were isolated by UltraCentrifugation or Exoquick-TC® methods. Preparations of melanoma-derived 
vesicles were characterized by using the Nanosight™ technology and the expression of exosome markers analyzed by 
western blot. The expression levels of endogenous and exosomal miRNAs were examined by real time PCR. Confocal 
microscopy was used to evaluate transfer and uptake of microvesicles from donor to recipient cells. The functional 
significance of exosomal miR-222 was estimated by analyzing the vessel-like process formation, as well as cell cycle 
rates, invasive and chemotactic capabilities.
Results: Besides microvesicle marker characterization, we evidenced that miR-222 exosomal expression mostly 
reflected its abundance in the cells of origin, correctly paralleled by repression of its target genes, such as p27Kip1, 
and induction of the PI3K/AKT pathway, thus confirming its functional implication in cancer. The possible differential 
significance of PI3K/AKT blockade was assessed by using the BKM120 inhibitor in miR-222-transduced cell lines. In 
addition, in vitro cultures showed that vesicles released by miR-222-overexpressing cells were able to transfer miR-
222-dependent malignancy when taken-up by recipient primary melanomas. Results were confirmed by antago-
miR-221&222 treatments and by functional observations after internalization of EXOs devoid of these miRs.
Conclusion: All together these data, besides generally confirming the role of miR-222 in melanoma tumorigenesis, 
supported its responsibility in the exosome-associated melanoma properties, thus further indicating this miR as 
potential diagnostic and prognostic biomarker and its abrogation as a future therapeutic option.
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Background
Malignant melanoma is the most aggressive form of 
skin cancer whose incidence is doubling almost every 
10 years. Although surgical resection is mostly a defini-
tive treatment at the primary stages of the disease, the 
survival of patients is strongly reduced after metastatic 
dissemination, mostly due to resistance to conventional 
therapies [1, 2]. Therefore it is important to use new 
molecular approaches in order to better understand the 
mechanisms underlying melanoma progression.
MicroRNAs (miRs) are non-coding RNAs that regu-
late gene expression mostly at post-transcriptional level 
playing important roles in nearly all the biological func-
tions, including tumor development and dissemination 
[3]. These small non coding RNAs have revealed a great 
potential as early diagnosis markers being highly stable 
and able to discriminate different subtypes of cancer [4]. 
Moreover the profile of circulating miRs was shown to 
reflect the expression pattern of tumor tissues [5].
Our previous results showed that miR-221&222 are key 
factors for melanoma development and dissemination, as 
they control the progression of the neoplasia through the 
down-modulation of several direct targets, as p27Kip1/
CDKN1B, c-KIT receptor and c-FOS, all playing antineo-
plastic functions. Accordingly the miR-221&222-depend-
ent repression leads to enhanced proliferation as well as 
differentiation and apoptosis blockade in melanoma cells 
[6, 7].
Growing evidence is showing that miRs are not strictly 
cellular, but are secreted in extracellular compartments, 
as body fluids as well as cell culture media, where they 
might be transported by vesicle and non vesicle carriers, 
including “exosomes” (EXO) [8]. EXOs are nanovesicles 
of diameter ranging between 50 to 140 nm, distinguished 
from other cell-derived vesicles by their origin, size, 
morphology and composition [9]. In fact, due to their 
endosomal origin, EXOs are enriched of certain pro-
teins, including members of the tetraspanin family (CD9, 
CD81, CD82, CD63), heat shock proteins (Hsp60, Hsp70, 
Hsp90) and proteins of the multivesicular bodies (annex-
ins, Rab GTPases and endosomal sorting complexes 
required for transport (ESCRT) proteins) [10]. EXOs 
secreted by tumor cells were shown to transfer oncogenic 
properties via horizontal propagation of mRNAs, miRs 
and proteins. More important, upon their release in the 
extracellular environment, EXOs are utilized by tumors 
for both local and distant cellular communications, as 
these nanoparticles are able to transfer their cargo into 
the acceptor cells in autocrine and paracrine fashions 
[11].
In this study, we evaluated whether the presence of 
increased levels of miR-222 into melanoma-released 
EXOs were able to transfer the aggressive behavior of 
the donors into the acceptor cells. We also evaluated the 
possible functional role of some miR-222-related mol-
ecules carried by purified EXOs in supporting melanoma 
malignancy.
Methods
Cell culture
Human melanoma cell lines were stabilized from sur-
gical specimens obtained from primary or metastatic 
tumors at Istituto Nazionale Tumori (Milan, Italy). Cell 
lines were characterized for growth in soft agar and, 
whenever possible, their metastatic potential was evalu-
ated into athymic nude mice. Early passages cells were 
obtained from bioptic specimens at Istituto Dermopatico 
dell’Immacolata (Rome, Italy). All biological materials 
were obtained with the informed consent of patients and 
the study was conducted according to the Declaration of 
Helsinki Principles. An institutional approval for the per-
formed experiments was not required. The cell lines were 
authenticated according to standard short tandem repeat 
(STR)-based genotyping. Melanoma cell lines were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM) 
(GIBCO by Life Technologies, Paisley, UK) supple-
mented with 10  % FBS (GIBCO). Cells were incubated 
at 37  °C and supplemented with 5 % CO2 in humidified 
chamber. When indicated, melanoma cell lines were len-
tivirally transduced with miR-222 as previously reported 
[6, 7, 12]. Treatments with NVP-BKM120 (Selleckchem, 
Houston, TX, USA), a PI3K specific pan inhibitor, were 
performed at doses ranging between 1 and 5 µM in syn-
chronized or not synchronized melanoma cells, in pres-
ence of 5 or 10 % FBS previously deprived of endogenous 
microvesicles by ultracentrifugation.
Exosome isolation and tracking analysis
EXOs were isolated from 24  h cell culture media by 
ultracentrifugation (UC) or Exoquick-TC (EQ) (Sys-
tem Biosciences, Mountain View, CA, USA) methods 
according to standards procedures or manufacturer’s 
instruction, with minor modifications (Fig. 1a). For exo-
some purification, serum was depleted of bovine EXOs 
by ultracentrifugation at 100,000×g for 6 h, followed by 
passing it through 0.2 µm filter prior to use. The protein 
concentration of EXOs was determined using a protein 
assay kit (Bio-Rad, Hercules, CA, USA) and in some 
cases the number and size of EXOs were directly tracked 
using the Nanosight NS300 system (Nanosight™ tech-
nology, Malvern, UK), configured with a 488  nm laser 
and a high-sensitivity sCMOS camera. Videos were col-
lected and analyzed using the NTA software (version 
3.0). For each sample, multiple videos of 60  s duration 
were recorded generating replicate histograms that were 
averaged.
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Exosome labeling and internalization
Cells were labeled by including into the culture medium 
(DMEM supplemented with 0.3  % FBS-UC) the fatty 
acid molecule BODIPY® FL C16. After 5  h of incuba-
tion, the dye in excess was washed out and cell culture 
media containing EXOs (with fluorescent phospholipids 
incorporated into membranes) were recovered. Thirty 
micrograms of EXOs (purified with EQ methods) were 
co-cultured with 2 × 104 recipient cells grown in eight-
well chamber slides (IBIDI, Martinried, Germany). After 
2–3 h of incubation, cells were fixed in 4 % w/v paraform-
aldehyde (Sigma–Aldrich) for 10  min. Next, cells were 
stained by Alexa Fluor 647 conjugate phalloidin (Immu-
nological Sciences, Rome, Italy) and nuclei by Hoechst 
333258 dye (Sigma–Aldrich). Exosomal and cellular 
staining were analyzed by Olympus FV-1000 laser-scan-
ning confocal microscopy.
In vitro experimental model of fusion and functional 
assays
The same amounts of EXO/Tween or EXO/miR-222 puri-
fied EXOs, recovered from conditioned media of mela-
noma cells transduced either with Tween empty vector or 
miR-222, were incubated with recipient cells for 30 min 
at 37 °C before performing expression studies and func-
tional assays. Vesicle preparations were used immediately 
after isolation. Invasion and chemotaxis studies were per-
formed according to standard procedures [6]. For tube 
formation assays, melanoma cells after being fused with 
EXOs were seeded into culture slide wells coated with 
100 mg/cm2 of Matrigel growth factor reduced (Becton–
Dickinson, Bedford, MA, USA). Tube-like formations 
defined as ≥2 cells forming elongated structures were 
counted after 24–48 h of incubation by microscope (JULI 
microscopy, Twin Helix, MI, Italy) at 10 × magnification 
from four different fields for each condition. Tube forma-
tion was analyzed manually [13] and by the Image J soft-
ware. Experiments were conducted at least three times.
MiR‑221 and miR‑222 silencing by antagomir treatment
Chemically modified antisense oligonucleotides (antag-
omir or αmiR) were used to inhibit miR expression [6]. 
The sequences of αmiR-221 and αmiR-222 used are: 
5′P-GAAACCCAGCAGACAAUGUAGCU-3′-Chl and 
5′P-GAGACCCAGUAGCCAGAUGUAGCU-3′-Chl, 
respectively; all the bases were 2′OMe modified. Antago-
mir oligonucleotides, were transfected at 200 nmol/L by 
using Lipofectamine 2000 (Invitrogen), according to the 
manufacturer’s procedures. As a control, an unrelated 
antagomir, specifically the antagomir targeting miR-
133a that is not expressed in melanomas (αmiR-133) was 
transfected as well. EXOs were purified from conditioned 
media 24 h after transfections.
Cell cycle analysis
Cell cycle analysis was performed in synchronized 
or not synchronized melanoma cells. In the first case 
cells were synchronized by the addition of Hydrox-
yurea (HU), final concentration 2  mM, per 16  h. Cul-
tures were then washed and medium replaced. From 
this point, considered as t  =  0, cells were monitored 
while they proceed along the cell cycle after specific 
treatments (i.e., EXO internalization or BKM120 sup-
plementation). In not synchronized experiments, cells 
were seeded at roughly 60–70 % confluence and treated 
as indicated in DMEM supplemented with 5  % FBS 
in triplicate. Cells were collected, washed in PBS, and 
suspended in propidium iodide (PI) staining buffer 
(PBS containing 1  % Triton X-100, 50  mg/ml PI and 
50 mg/ml RNase). Cells were then incubated for 30 min 
(37 °C) and DNA content measured by flow cytometry 
using a BD FACS Canto cytometer (BD Biosciences, 
CA, USA).
Western blot
Western blot analysis was performed according to 
standard procedures. Exosome samples were lysed in 
buffer (0.5  % Triton; 300  mM NaCl; 50  mM TrisNaCl) 
supplemented with protease inhibitor cocktail. Anti-
bodies listed below were used in accordance to the man-
ufacturer’s instructions: CD63 (SBI System Biosciences, 
Mountain View, CA, USA), RAB5B, TSG101, HSP90 
and CycD1 (Santa Cruz Biotechnology Dallas, TX; 
USA), LAMP2 and CAV-1 (BD Biosciences, CA, USA), 
RAB27A (Abnova, Taipei City, Taiwan), p85β (Abcam, 
Cambridge, MA, USA), AKT, ph-AKTSer473 and p27Kip1 
(Cell Signaling, Beverly, MA, USA). β-ACTIN (Oncogene 
Research, La Jolla, CA, USA) was used as a loading con-
trol and subsequent quantification. The expression levels 
were evaluated by the AlphaView (Protein-simple, CA, 
USA) or Image Quant Software (Uppsala, Sweden).
RNA preparation and qRT‑PCR
RNA was isolated from cell lines and EXOs using the 
“Total RNA Purification micro Kit” (NorgenBioteK 
Corp, Canada) according to the manufacturer’s proto-
col. In the first setting of experiment, to avoid any pos-
sible contamination of external RNAs, before exosome 
purification conditioned media were pre-treated with 
RNase (Roche, Nutley, NJ, USA) for 10 min at 37 °C. Real 
time quantification (qRT-PCR) of miR-222 (#000525), 
p27Kip1 (#Hs00153277_m1), FGF2 (#Hs00266645_m1), 
VEGFA (#Hs000900055_m1), ITGβ3 (#Hs00173978_m1) 
and Bcl-2 (#Hs00153350_m1) were performed according 
to the TaqMan technology (Applied Biosystems, Foster 
City, CA, USA). MiR-16 (#000391), RNU6B (#001093) 
and GAPDH (4326317E) were used as internal controls. 
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The expression profile of Human Tumor metastasis genes 
was performed using the TaqMan Array 96-Well Plate 
(#4414229) (Applied Biosystems, Foster City, CA, USA).
Statistical analysis
Differences were statistically evaluated using Student’s 
t test. p  <  0.05 was defined as statistically significant. 
ANOVA analysis was performed using GraphPad version 
4.0 for Windows (GraphPad Software, San Diego, CA) 
followed by Student–Newman–Keuls post hoc test when 
appropriate.
Results
Characterization of melanoma purified EXOs
MiR-222 overexpression is involved in the poor progno-
sis of several tumors where it was demonstrated to pro-
mote cell growth, migration and invasion and to inhibit 
apoptosis [14, 15]. In addition circulating miR-222 has 
been proposed as diagnostic and prognostic marker [16].
In view of the tumorigenic role played by miR-222 in 
melanoma, we evaluated the exosome capability of car-
rying miR-222 and its associated properties. For this pur-
pose EXOs were purified, either by ultracentrifugation 
(UC) or Exoquick-TC (EQ) methods, from conditioned 
media of stabilized and early passage melanoma cell 
lines at different stages of progression (Fig. 1a). Accord-
ing to the general trend of miR-222 enhancement associ-
ated with melanoma advancement [6], qRT-PCR analysis 
revealed that EXOs, either UC- or EQ-purified, released 
by metastatic cells contained higher levels of miR-222 
in comparison with primary melanomas (Fig. 1b). More 
important, to rule out any possible artifact due to cell 
cultures, this expression pattern was confirmed in mela-
noma cell lines analyzed at early times after surgical exci-
sion and in the corresponding released EXOs (Fig. 1c).
To investigate the functionality of miR-222 in exosome-
mediated tumorigenesis, we lentivirally transduced the 
Tween control vector or miR-222 in two melanoma cell 
lines, Me1007 and Me1402/R, early primary and recur-
rence of primary melanoma, selected in view of their 
low endogenous levels of this miR (Fig. 1b) [6]. qRT-PCR 
analysis confirmed the significant relative up-regulation 
of miR-222 in miR-transduced Me1007 and Me1402/R 
(10-fold and 12-fold, respectively) in comparison with 
levels detected in vector-transduced melanoma cell lines 
(Fig.  2a). Notably, similar increments of miR-222 were 
detected in the corresponding EXOs (6-fold for EXOs 
secreted by Me1007 and 12-fold for those released by 
Me1402/R) (Fig. 2a).
Melanoma-derived vesicles were then character-
ized for their size distribution by using the Nanosight™ 
technology. Results showed similar profiles for UC- and 
EQ-derived EXOs, with nanoparticles ranging between 
70 and 140  nm, with a mean value of 100  nm, in both 
control and miR-222 overexpressing cells (Fig. 2b, c and 
data not shown). The amount of melanoma-released 
EXOs was also assessed by using either the Nanosight™ 
technology or the Bradford assay for protein quantita-
tion. In both cases results revealed that miR-222-trans-
duced melanomas secreted a significantly higher 
number of EXOs compared with control cells, possibly 
suggesting a role for miR-222 in the EXO releasing pro-
cess (Fig. 2d).
The protein content of these EXOs analyzed by west-
ern blot showed a miR-222-dependent enrichment for 
proteins commonly utilized as exosomal markers, such 
as LAMP2, HSP90, CD63 and RAB5B, (Fig. 2e). In addi-
tion, besides confirming miR-222 overexpression into 
the exosomal cargo (Fig. 2a), we observed reduced levels 
of p27Kip1, a negative regulator of cell cycle previously 
demonstrated as a direct target of this miR [6]. These 
results suggested that miR-222 was somehow func-
tional in the vesicular fraction (Fig.  2e). Accordingly, in 
Me1402/R we detected a miR-222-dependent increase of 
CAV-1 and RAB27A, proteins already described for their 
involvement in exosome uptakes and secretory pathways 
[17–19]. Although CAV-1 and RAB27A are expressed 
in Me1007 cells, we were unable to detect them in the 
corresponding EXOs, likely because of their low levels. 
As internal loading controls, we utilized TSG101 and 
β-ACTIN which appeared constantly expressed (Fig. 2e).
In vitro functional studies on EXO/miR‑222
To determine whether the EXO/miR-222 and their 
cargo could be taken up by recipient cells, we utilized 
an in  vitro experimental model where EXOs isolated 
from donor cells were incubated with control melanoma 
cell lines. Specifically the same amounts of EXOs, puri-
fied either from miR-222- or from empty vector-trans-
duced melanoma cells, were incubated with Me1007 or 
Me1402/R acceptor cells.
To visualize the actual internalization of the vesicles 
and the effectiveness of miR-222 transfer from donor 
into acceptor cells, Me1007/miR-222 cells were stained 
with the fluorescent fatty acid molecule BODIPY® FL 
C16 which, being incorporated into membrane phos-
pholipids, made possible EXOs’ labeling and in turn visu-
alization. Me1007 cells and miR-222-containing labeled 
EXOs were then incubated for 2  h at 37  °C before con-
focal microscopy evaluation. Control untreated and exo-
some fused cells were stained by phalloidin (Alexa Fluor 
647, red) and by the nuclear Hoechst dye (blue). The 
internalization of EXOs was evidenced by a green fluo-
rescent punctuate signal inside the cytoplasm of Me1007 
recipient cells (Fig. 3a). Similar results were obtained in 
Me1402/R cellular model (data not shown).
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Fig. 1 Exosomes (EXOs) purification and miR-222 expression analysis in melanoma. a Flow chart outlining the main steps of exosome isolation 
from cell culture supernatants. EXOs were purified from 24 h cell culture media by ultracentrifugation (UC) (left panel) or Exoquick-TC (EQ) (right 
panel) methods. miR-222 levels were compared by qRT-PCR in b stabilized melanoma cell lines and corresponding EXOs either UC (EXO UC) or EQ 
(EXO EQ) purified and c in early passages melanoma cell lines and corresponding EXOs. Me1007 primary melanoma cell line was used as an internal 
control to compare the two groups. Columns, mean ± SD of at least three independent experiments
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Fig. 2 Characterization of melanoma exosomes. a Representative qRT-PCR in miR-222- and empty vector-transduced melanoma cells and cor-
responding exosomes (EXO EQ). Relative miR expression levels were normalized on miR-16 (for EXOs) or RNU6B (for cells). b, c Size distribution of 
Me1402/R UC and EQ purified vesicles analyzed by the Nanosight™ technology. Graph bars represent the mean size of the particles ±SD, whereas 
the mode, shown as a single point overlying the graphs, indicates the most often occurring dimension. d The relative amounts of melanoma-derived 
EXOs were assessed by using the Nanosight™ technology (left) or by the Bradford assay for protein quantization (right). e WB analysis of specific 
‘‘exosome-enriched’’ proteins in EXOs purified from Me1007 and Me1402/R melanomas by the EQ method. β-Actin was utilized as internal loading 
control for each experiment. Columns, mean ± SD of at least three independent experiments. *p < 0.05; **p < 0.01
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Fig. 3 Evaluation of exosome uptake by recipient cells. a Confocal microscopy visualization of untreated (top) and exosome fused (bottom) Me1007 
cell line. Me1007/miR-222 donor cells were labeled with the fluorescent BODIPY® FL C16 fatty acid molecule, which being incorporated into the 
EXO membranes allowed visualizing these vesicles. Me1007 recipient cells were stained for phalloidin (Alexa Fluor 647-red) and nuclei counter-
stained with Hoechst. Bodipy C16-labelled exosomes appear as internalized green dots. Scale bar 10 μm. b The uptake of miR-222-containing 
exosomes by the acceptor Me1007 and Me1402/R melanomas was quantified by specific qRT-PCR (miR-222/RNU6B). Data are cumulative of three 
independent experiments. Differences in miR-222 expression were evaluated using analysis of variance (ANOVA) followed by a Newman–Keuls post 
hoc test. Significance was accepted when the p value was <0.05. c The downregulation of p27Kip1, a direct target of miR-222, by EXO/miR-222 was 
evaluated by qRT-PCR. d Cell cycle analysis, showing the miR-222-dependent early onset of DNA synthesis, was performed on synchronized cells 
2 h after exosome internalization. e, f EXO-dependent effects on invasion (left panels) and chemotaxis (right panels) in Me1007 and Me1402/R mela-
noma cell lines. MiR-222-transduced cells were included as a positive control. Data are representative of two independent experiments. *p < 0.05; 
**p < 0.01
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Above all the horizontal transfer was confirmed by 
specific qRT-PCR for miR-222. Indeed the uptake of 
miR-222-containing EXOs by the acceptor melanoma 
cells produced 3-fold increase of miR-222 respect to its 
basal expression in Me1402/R/Tween cells and 1.5-fold 
respect to the homologous control fusion with EXO/
Tween (Fig.  3b right). Similar results were obtained in 
Me1007 melanoma cells (2.5-fold increase of miR-222 
respect to its basal cellular expression and 1.3-fold respect 
to the EXO/Tween control Fig. 3b left). Of note was the 
downregulation of p27Kip1 consequent to EXO/miR-222 
internalization comparable to that obtained by miR-222 
lentiviral-induced overexpression (Fig.  3c). In addition 
the horizontal transfer was confirmed by changes of some 
other relevant molecules. As suggested by their higher 
expression in EXO/miR-222 respect to EXO/Tween 
(Fig.  2e), we observed the exosome-related capability to 
convey vesicle-markers possibly associated with tumori-
genesis, such as CD63, CAV-1, RAB5B and RAB27A, into 
the acceptor cells (Additional file 1: Fig. S1).
Basing on these results, we searched for any tumo-
rigenic effect possibly associated with EXO/miR-222. 
At first, and in view of p27Kip1 decrease, we evaluated 
the cell cycle rate possibly modulated as a consequence 
of EXO/miR-222 internalization. As already shown for 
melanoma cells overexpressing miR-221 or miR-222, 
where previous analyses revealed an early onset of DNA 
synthesis paralleled by G0/G1 reduction [6], we detected 
an increased proliferative rate when Me1402/R cells were 
incubated with EXOs enriched for miR-222. Specifically, 
2 h after serum stimulation cell cycle evaluation showed 
either in control or in EXO/Tween treated: 75–78  % of 
the cells in G0/G1, 7–8 % in S and 14–18 % in G2/M. Val-
ues were modified by EXO/miR-222 uptake up to 62  % 
G0/G1, 8 % S and 30 % G2/M (Fig. 3d). Also by using a 
Boyden chamber assay we observed a small, but signifi-
cant EXO/miR-222-dependent induction of the invasive 
and chemotactic capabilities (Fig.  3e, f ). More evident 
was the different capability in the vessel-like process 
formation, which partly mimics melanoma aggressive-
ness [13]. Indeed the EXO/miR-222 fusion enhanced the 
capability of forming vascular-like structures by Me1007 
and Me1402/R (Fig. 4a, b).
The reverse effects were obtained with EXOs recov-
ered after inhibition of endogenous miR-221 and miR-
222 by antagomir transfections. The choice of abrogating 
both miRs derive from their possible redundant roles 
based on the high number of shared target genes [6]. 
Previous studies showed reduced cell proliferation and 
slight decrease in invasion and migration abilities in 
melanoma cell lines transfected with these highly sta-
ble oligomers showed [6]. Accordingly, we observed 
the antago-dependent reduction of the PI3K/AKT and 
cyclin D1 (CycD1) axis, together with the upregulation of 
p27Kip1 (Fig. 5a). In line with miR-221&222 abrogation, 
the antagomir-carrying EXOs were able to reduce the 
cell cycle rate of melanoma acceptor cells (EXO/αmiR-
221&222 treatment: 82  % of the cells in G0/G1, 17  % 
in S, 1 % in G2/M vs control or EXO/Tween treatment: 
57–62 % in G0/G1, 34–39 % in S, 4 % in G2/M) (Fig. 5b). 
Yet again more evident differences were detected in the 
formation of vascular-like structures resulting reduced 
and less organized by the αmiR-221&222/EXO internali-
zation (Fig. 5c). In line with these functional effects, we 
detected the regulation of some key factors involved in 
cell growth, apoptosis and tube formation, in particular 
reduction of Bcl2, ITGβ3, FGF2 and VEGF (Fig. 5d). The 
specificity of miR-222 down-regulation was confirmed by 
qRT-PCR (Fig. 5e).
Activation of the PI3K/AKT pathway by EXO‑miR‑222
As the PI3K/AKT pathway is frequently deregulated 
in cancer, the main components of this axis represent 
attractive candidates for targeting. A growing body of 
evidence has shown that MAPK and PI3K signaling play 
major roles in melanoma development and progression 
[20]. In addition the expression of miR-221 and miR-222 
has been reported to be under the positive control of the 
RAS/MAPK [21, 22] and upstream to PI3K/AKT signal-
ing in different cellular models [23, 24]. As miR-221&222 
deregulation has been associated with these tumo-
rigenic pathways and circulating miR-222 was suggested 
as a possible tumor biomarker [25–28], we evaluated 
whether EXOs secreted by miR-222-overexpressing cells 
might be able to induce an oncogenic program through 
the horizontal transfer of miR-222 itself as well as of 
related molecules. Expression studies confirmed a miR-
222-dependent upregulation of the PI3K/p85β subunit in 
both melanoma cells and EXOs (Fig. 6a) and the reverse 
results in antagomiR-221&222 treated cells (Fig. 5a). We 
then investigated whether the transfer of EXO/miR-222 
might be sufficient to modulate the PI3K/AKT pathway 
after internalization into the recipient cells. Western blot 
analysis showed the increase of PI3K/p85β and ph-AKT-
Ser473, key molecules involved in this signaling, up to lev-
els similar to those of miR-222-transduced cells (Fig. 6b). 
Densitometric quantifications of total AKT and its Ser473 
phosphorylated fraction confirmed the increased ph-
AKTSer473/total AKT ratios associated with miR-222 
(Fig. 6c).
To assess the possible differential significance of PI3K 
blockade in control vs miR-222-transduced cell lines, we 
treated either synchronized or not synchronized mela-
noma cells with NVP-BKM120, a potent class I PI3K 
pure pan inhibitor, at doses ranging between 2.5 and 
5 µM. Results were evaluated on cell cycle rates. In both 
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treatments, miR-222 overexpression seemed to inter-
fere with BKM120-dependent effects. In hydroxyurea-
blocked cells, the 2  h cell cycle determination showed 
the miR-222-dependent earlier onset of DNA synthe-
sis in both untreated and BKM120-treated Me1007/
miR-222 compared with control vector transduced cells 
(Fig. 7a). When the effects of BKM120 were evaluated on 
proliferating melanoma cells, miR-222 seemed to inter-
fere with the BKM120-dependent block in the G2/M 
phase (Fig. 7c). Western blot analyses and densitometric 
quantitations confirmed ph-AKTSer473 and PI3K/p85β 
downregulation (Fig. 7b, d and Additional file 2: Fig. S2).
To further dissect the role of miR-222 in the exosome 
cargo of Me1402/R melanoma, we compared the expres-
sion profiles of EXO/miR-222 and EXO/Tween by using 
the TaqMan array plate for human tumor metastasis 
genes (Additional file  3: Fig. S3A). Although current 
reports have shown that a fraction of the RNAs present 
in EXOs could be somewhat degraded, the presence of 
some poly-adenylated RNAs was also reported [29, 30]. 
Fig. 4 In vitro functional studies in Me1007 and Me1402/R. a Morphological and b quantitative analyses of tube formation and length in Tween- 
and miR-222-transduced melanoma cells compared with EXO/Tween or EXO/miR-222 fused Me1007 or Me1402/R cells. Purified exosomes were 
incubated with recipient cells for 30 min at 37 °C before performing functional assays. Tube formation was analyzed 20 h after exosome internaliza-
tion. Data are representative of three independent experiments. *p < 0.05; **p < 0.01
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Fig. 5 Effects on melanoma tumorigenesis of antagomir-221&222 carried by EXOs. Melanoma cells treated with control antagomir-133 (αmiR-133)- 
or antagomir-221&222 (αmiR-221 + 222)-EXOs were compared for a modulation of protein expression by western blot, b cell cycle rate, c tube-like 
formation capability evaluated at 20 h and 2 days after EXO internalization. qRT-PCR evaluation of d miR-222 related molecules and e miR-222 
itself to confirm its inhibition. Relative miR expression levels were normalized on RNU6B. Data are representative of two independent experiments. 
*p < 0.05; **p < 0.01. β-Actin and GAPDH were utilized as internal controls
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As possibly expected in view of the low amounts of RNA 
recovered from EXOs, qRT-PCR analyses revealed that 
the majority of genes exhibited Ct values higher than 35. 
Even so, in agreement with miR-222 tumor promoting 
function, we observed the up-regulation of a number of 
genes involved in melanoma progression. Among them 
we found the miR-222-based upregulation of VEGF and 
FGF2 well known to play major roles in melanoma cell 
growth and tumor angiogenesis according to autocrine 
and paracrine functions [31, 32]. Interestingly, some 
other factors, as the MGAT5, MCAM and TGFβ1, coop-
erating in the induction of prometastatic phenotypes in 
melanoma [33, 34], were induced by miR-222. Finally, 
among the few genes downregulated in EXO/miR-222 
we detected MTA1 and MTA2, nuclear receptor coregu-
lators overexpressed in human cancers, but reported to 
play a dual role being either corepressors or coactivators 
[35]. The accuracy of these microarray results was vali-
dated by qRT-PCR of FGF2 and VEGF genes (Additional 
file 3: Fig. S3B).
Discussion
MiRs are non-coding RNAs regulating gene expression 
mostly at post-transcriptional level [36]. Growing evi-
dences are showing their functional involvement in all the 
main biological processes, including cancer development 
and progression, where they can act either as oncogenes 
or tumor suppressors [3]. Besides their cellular associa-
tion, recent data demonstrated miRs to be secreted in the 
extracellular compartments as free molecules or carried 
by microvesicles, thus transferring information at local 
and distant sites [30].
Several groups have focused their attention on miR-221 
and miR-222 reported to drive the oncogenesis of many 
types of malignancies by directly repressing a number of 
tumor suppressor genes and activating oncogenic path-
ways [14]. Focusing on melanoma, we previously showed 
that miR-221&222 play a dynamic role regulating prolif-
eration and progression repressing several antineoplas-
tic targets (e.g., p27Kip1/CDKN1B, c-KIT receptor and 
c-FOS) [6, 7].
Here we show that miR-222, being part of melanoma 
exosomal cargo, can be transferred between cells result-
ing per se able to promote tumorigenesis through the 
activation of several molecules, including the PI3K/AKT 
pathway.
Since a definite consensus on the ‘‘correct’’ technique 
to isolate EXOs is still lacking [37], we utilized and 
compared ultracentrifugation and Exoquick alternative 
methods. Purified EXOs, analyzed by NanoSight and/
or western blot technologies, showed the same distri-
bution as well as similar enrichment for some vesicular 
proteins, as LAMP2, CD63, RAB5B, TSG101, HSP90 and 
β-ACTIN (Fig. 2). In agreement with the general gradual 
increase of miR-222 associated with melanoma progres-
sion, either in stabilized or early passage cell lines, we 
detected the same expression pattern in the correspond-
ing EXOs (Fig. 1). Moreover a significant accumulation of 
this miR was detectable in EXOs purified from primary 
melanoma cell lines (Me1007 and Me1402/R) enforced to 
express miR-222 (Fig. 2). Indeed the mature sequence of 
Fig. 6 WB analysis of proteins modulated by EXO/miR-222 in Me1007 
and Me1402/R melanomas. a Western blot analysis of PI3K/p85β 
subunit in Tween control vs miR-222-transduced cells and corre-
sponding EXOs (left panel) and relative densitometric quantification 
(right panel). b Western blot analysis of PI3K/AKT related proteins after 
fusion of either EXO/Tween or EXO/miR-222 with Tween-transduced 
melanomas. β-Actin was utilized as internal loading control. c Quan-
tification of ph-AKTSer473/Akt ratios. Mean ± SD of three independent 
experiments *p < 0.05
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miR-222 contains two short sequence motifs reported to 
function as exosomal packaging signals or miR intracel-
lular retaining [38].
Previous studies already provided evidences of exo-
some transfer and content deliver from donors to recipi-
ent cells [30, 39]. Utilizing an experimental model, we got 
higher invasive and chemotactic capabilities and, even 
more evident, vessel-like process formation associated 
with EXO/miR-222 internalization into primary melano-
mas, indicating increased melanoma malignancy (Figs. 3, 
4) [13]. The reverse effects obtained after internaliza-
tion of EXOαmir-221&222 supported our conclusions 
(Fig. 5). An analogous EXO-based increase of malignancy 
was described for miR-10b in breast cancer [9, 40] where 
miR-10b was associated with the risk of relapse [41, 42].
Trying to dissect the downstream pathways regulated 
by miR-222, we demonstrated, either in melanoma cells 
or secreted EXOs, the miR-222-dependent induction of 
the PI3K/AKT pathway, associated with the expected 
downregulation of miR-222 direct target p27Kip1. As 
no significant differences were detected in the cell-cycle 
rates of miR-222-overexpressing cells treated or not with 
the AKT inhibitor BKM120 (Fig. 7a), we considered the 
capability of miR-222 to overcome the inhibition of the 
PI3K/AKT pathway, on one side considering the frequent 
constitutive activation of the MAPK axis, on the other 
the number of genes inhibiting proliferation, inducing 
apoptosis or generally playing tumor suppressor func-
tions, known to be directly targeted by miR-222 [14]. In 
addition PI3K/p85β was identified as a direct target of 
miR-126, that we recently demonstrated as part of a cross 
regulatory circuitry linking the oncomiR-221&222 with 
the tumor suppressors miR-126&126*. During melanoma 
progression, the expression levels of these two couples 
of miRs functionally move from miR-126&126* toward 
miR-221&222 under the regulation of the transcription 
factor AP2α [43]. In line with their opposite roles, protein 
analyses confirmed that several miR-126&126* targeted 
genes were induced by miR-221&222, including AKT and 
PI3K/p85β.
According to the reported association between the 
number of released EXOs and tumor malignancy [19], 
miR-222 seemed also to augment the amount of secreted 
EXOs per cell. In agreement with their functional roles 
recently associated with cancer, some exosomal markers 
resulted upregulated by miR-222 (Fig.  2). Among them, 
RAB GTPases were implicated in membrane trafficking 
and exosome secretion in melanoma. Specifically RAB5B 
Fig. 7 Effects of miR-222 overexpression on the inhibition of PI3K/AKT axis. Cell cycle analysis of miR-222-transduced vs control cells treated with 
2.5 and 5 µM of BKM 120 in a synchronized Me1007 and c proliferating Me1402/R. b and d Relative densitometric quantification of western blot 
performed in the same cells. β-Actin was utilized as internal loading control. Data are representative of two independent experiments. *p < 0.05; 
**p < 0.01
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and RAB27 were shown to increase the release and trans-
fer capability of the microvesicles being involved in tumor 
metastatization including melanoma [19, 44–46]. Also 
the tetraspanin CD63, a well known marker of microvesi-
cles, was associated with prometastatic pathways [47] 
and evidenced together with Cav1 on plasma EXOs of 
melanoma patients [18]. Previous studies linked Cav1 
overexpression with melanoma malignancy showing that 
its secreted amounts loaded in the exosomal cargo were 
involved in cell migration [17, 48]. Indeed, recent studies 
supported the notion of the pro-metastatic role of CD63 
through β-catenin induction and subsequent increase of 
ERK phosphorylation and PI3K/AKT pathway activity 
[47, 49, 50]. Although these increases might suggest the 
involvement of miR-222 in the EXO releasing process, at 
present no significant data directly correlate these exoso-
mal markers with miR-222.
The expression profiles obtained by analyzing a panel 
of tumor metastasis genes further demonstrated the 
presence of higher levels of tumor promoting genes in 
EXO/miR-222. Among them we found MGAT5, which in 
melanoma plays a role during the transition from the ver-
tical growth phase to the metastatic stage, together with 
its targets MCAM [33], and TGFβ expressed in most 
malignant melanomas and correlating with poor survival 
[51]. Last but not least the increased levels of the growth 
factors VEGF and FGF2 found into the exosome cargo 
(Additional file 3: Fig. S3A), besides underlying the miR-
222 induction of vascular-like structures, suggested the 
exosome-based transport to explain the unconventional 
leaderless secretion of FGF2 [52].
Conclusions
The growing understanding of cancer cell-derived vesi-
cles, exosome-mediated uptake and transfer of the 
molecular cargos is making more realistic to easily evalu-
ate EXOs in plasma from patients. Our results implicate 
miR-222, either cell-associated or exosome-transported, 
as a regulator of melanoma malignancy (Additional file 3: 
Fig. S3C), suggesting its potential validity as diagnos-
tic and prognostic biomarker. Indeed, as miR-222 was 
reported to be under the positive control of the RAS/
MAPK and upstream to PI3K/AKT signaling, its abroga-
tion might represent a promising therapeutic option.
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